Clinical Trial

Neurocognition in Schizophrenia

Study Description

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Memantine

To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.

Drug - Placebos

To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.

Additional Information

Official Study Title

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

Clinical Trial ID

NCT03860597

ParticipAid ID

b4xvgb